Patterns of levetiracetam and lacosamide use for treatment of status epilepticus with respect to clinical features and prior antiseizure medications.

BMC Neurol · 2026 · PMC13169792 · PMID 41928121

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

not quite significantp = 0.094so close (0.05 < p ≤ 0.1)

Furthermore, when including cases in which another second-line IV ASM was administered after the failure of a previous second-line IV ASM, LCM demonstrated a higher overall response rate compared to LEV, but the difference was not quite significant (57.4% vs. 40%; p = 0.094).

also in 653 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.